#Glioblastoma #UP Oncolytics #Rosalind Franklin University

Innovative Glioblastoma Therapy Shows Promise at National Conference

Recently, UP Oncolytics, an incubator company of Rosalind Franklin University, presented groundbreaking findings on a novel glioblastoma treatment at the American Association of Cancer Research (AACR) Special Conference on Brain Cancer held in Philadelphia. This conference, which took place from March 23 to March 25, attracted attention due to the potential of the therapy developed using Zika virus-based oncolytic technology. This innovative approach addresses glioblastoma's resistance to treatment and aims to improve patient outcomes significantly.

Overview of Glioblastoma

Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with a stark reality; it is one of the most deadly forms of cancer. In the United States, an estimated 13,000 new cases are diagnosed annually, with a disheartening median survival rate of merely 14 months. For two decades, the search for effective FDA-approved treatments has yielded little success, making the need for innovative solutions paramount.

Promising Studies Presented

In their presentations, UP Oncolytics unveiled results from two significant studies assessing the effectiveness of the Zika virus-based therapy. The first study, titled **